Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

Emanuele Pontali, Stefano Volpi, Giancarlo Antonucci, Marco Castellaneta, Davide Buzzi, Francesca Tricerri, Alessia Angelelli, Roberta Caorsi, Marcello Feasi, Francesca Calautti, Elio Castagnola, Gian Andrea Rollandi, Angelo Ravelli, Giovanni Cassola, Marco Gattorno

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)213-215
Number of pages3
JournalJ. Allergy Clin. Immunol.
Volume146
Issue number1
DOIs
Publication statusPublished - Jul 2020

Keywords

  • Administration, Intravenous
  • Adult
  • Antirheumatic Agents/administration & dosage
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections/complications
  • Female
  • Humans
  • Interleukin 1 Receptor Antagonist Protein/administration & dosage
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral/complications
  • SARS-CoV-2
  • Treatment Outcome

Cite this